Clinical Effectiveness of Triple Drug Therapy Combination Containing LABA, LAMA, and ICS Given for 12 Weeks in NS-COPD Patients

Background: Non-smoking chronic obstructive pulmonary disease (NS-COPD) poses unique challenges due to its distinct etiologies, such as environmental and occupational exposures.The clinical evidence on the effectiveness of triple-drug therapy, long-acting 2-agonist (LABA), long-acting muscarinic antagonist (LAMA), inhaled corticosteroid (ICS) in NS-COPD remains limited.Objective: To evaluate the clinical effectiveness of triple-drug therapy in NS-COPD patients.Materials and methods: A 12-month prospective observational study was conducted among NS-COPD patients treated with a single dry powder inhaler containing LABA, LAMA, and ICS combination (Fluticasone/Formoterol/Glycopyrrolate) for 12 weeks in a tertiary care hospital.The key parameters that were studied included spirometry, 6-minute walk distance(6MWD), COPD assessment test (CAT) score, St. George Respiratory Questionnaire (SGRQ), Modified Medical Research Council grading, body-mass index, obstruction, dyspnea and exercise (BODE) index, and occupational history.Results: Significant improvements were observed across all parameters after 12 weeks of therapy.Forced expiratory volume in 1 second improved from 62.3% 4.1 to 68.7% 3.9% predicted (p < 0.001), and 6MWD increased from 320.5 45.2 to 365.7 43.8 m (p < 0.01).The CAT score decreased significantly (18.4 3.6 to 13.2 3.1, p < 0.001), while SGRQ scores showed notable improvement (52.5 6.7 to 44.2 6.1, p < 0.001).Occupational exposure analysis indicated a significant correlation with the severity of COPD disease.Conclusion: Triple-drug therapy significantly improves respiratory functions, exercise capacity, and quality of life in NS-COPD patients, highlighting its clinical utility in this subset of patients.Further studies are warranted to study its long-term effects on exacerbations and mortality benefits.